Pre-emptive treatment of recurrent hepatitis C infection.
D000998:Antiviral Agents / Q000627:therapeutic use*; D006084:Graft Rejection / Q000276:immunology; D006526:Hepatitis C / Q000188:drug therapy / Q000517:prevention & control* / Q000601:surgery; D006801:Humans; D007121:Immunocompetence; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000627:therapeutic use; D016031:Liver Transplantation; D011092:Polyethylene Glycols / Q000627:therapeutic use; D011183:Postoperative Complications / Q000517:prevention & control; D011184:Postoperative Period; D011994:Recombinant Proteins; D055502:Secondary Prevention
D000998:Antiviral Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; C100416:peginterferon alfa-2a